Date: 6th September, 2013 Your Name: YiJun Dai

Manuscript Title: Etoposide soft capsule combined with anlotinib in the third-line treatment of advanced non-small cell lung cancer: a retrospective study

Manuscript number (if known): JTD-23-1412

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	No. 2018-2-26	The Youth Project of Health and Family Planning Commission
		Time frame: pas	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending	None	
	meetings and/or travel		
			Mais a Share to the second sec
			THE RESERVE OF THE PARTY OF THE
8	Patents planned, issued or	None	
	pending	None	
9	Participation on a Data	None	
	Safety Monitoring Board or	None	
	Advisory Board		A STATE OF THE STA
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
212	group, paid or unpaid		
11	Stock or stock options	None	
.2	0 111		
. 2	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	900000000	A STATE OF THE PARTY OF THE PAR
	financial interests	None	
-	- Interests		

The author reports that this study v	was supported by the Youth Proje	ct of Health and Fami	ly Planning Comm	ission (No. 2018-2-26)	
	1.652.1.154				

Please place an "X" next to the following statement to indicate your agreement:

Date: 6th September, 2023 Your Name: Yourn Qin

Manuscript Title: Etoposide soft capsule combined with anlotinib in the third-line treatment of advanced non-

small cell lung cancer: a retrospective study Manuscript number (if known): JTD-23-1412

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	\$4 \$4 \$4 \$4 \$4 \$4 \$5 \$5 \$1 \$1 \$1 \$1	Time frame: Since the initi	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	No. 2018-2-26	The Youth Project of Health and Family Planning Commission
		Time frame: pa	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	None	
	lectures, presentations, speakers bureaus,	None	
	manuscript writing or educational events		
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

I have no conflicts of inte	rest to declare.	41137.78	Tier.	
	4.63(0)339			

Please place an "X" next to the following statement to indicate your agreement:

Date: 6th September, 2023

Your Name: Jianguang Lin
Manuscript Title: Etoposide soft capsule combined with anlotinib in the third-line treatment of advanced non-

small cell lung cancer: a retrospective study Manuscript number (if known): JTD-23-1412

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	No. 2018-2-26	The Youth Project of Health and Family Planning Commission
		Time frame: pa	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	None	
,	lectures, presentations,	ivone	
	speakers bureaus,		
	manuscript writing or		TO THE REAL PROPERTY OF THE PARTY OF THE PAR
	educational events		
6	Payment for expert	News	
N. Test	testimony	None	
7	Support for attending	None	
	meetings and/or travel	None	
	0 3 4 4 4 4 4 4		
		A DESCRIPTION OF THE PARTY OF T	
8	Patents planned in		
•	Patents planned, issued or pending	None	
	Periumg		
9	Participation on a Data		
	Safety Monitoring Board or	None	
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,	None	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
2	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
13	Services Other financial		
13	Other financial or non- financial interests	None	
137	mancial interests	Laborate Line	
			The second secon

The author reports that this study was supported by the Youth Project of Health and Family Planning Commission (No. 2018-2-26)	
	1100
	1500

Please place an "X" next to the following statement to indicate your agreement:

Date: 6th september, 2023 Your Name: Yangbin Dai

Manuscript Title: Etoposide soft capsule combined with anlotinib in the third-line treatment of advanced non-

small cell lung cancer: a retrospective study Manuscript number (if known): JTD-23-1412

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
_		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	No. 2018-2-26	The Youth Project of Health and Family Planning Commission
		Time frame: pa	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
	Royalties or licenses	None	
	Consulting fees	None	

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending	None	
	meetings and/or travel		
		Constitution of the Consti	
			The state of the s
8	Patents planned in		
	Patents planned, issued or pending	None	
	perioring		
9	Participation on a Data		
	Safety Monitoring Board or	None	
	Advisory Board		
10	Leadership or fiduciary role		
	in other board, society,	None	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
		None	
2	Receipt of equipment,	None	
	materials, drugs, medical	one	
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		The state of the s

Please place an "X" next to the following statement to indicate your agreement:

Date: 6th September, 2023 Your Name: Yuncia Su

Manuscript Title: Etoposide soft capsule combined with anlotinib in the third-line treatment of advanced non-

small cell lung cancer: a retrospective study Manuscript number (if known): JTD-23-1412

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	No. 2018-2-26	The Youth Project of Health and Family Planning Commission
	L-Ste	Time frame: pas	t 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
	Royalties or licenses	None	
	Consulting fees	None	

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
-			
7	Support for attending	None	
	meetings and/or travel		
		Military and a second	
_			
8	Patents planned, issued or	None	
	pending		
9	D		
9	Participation on a Data	None	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role		
	in other board, society,	None	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-		
13	financial interests	None	
146	dicidi iliterests		

e author reports that this study was supported b	y the Youth Project of l	Health and Family	Planning Commis	sion (No. 2018-	2-26)	
	15-7-10	13 13	3 37		77.7	

Please place an "X" next to the following statement to indicate your agreement:

Date: 6 th September 2023 Your Name: Tadaaki Jamada

Manuscript Title: Etoposide soft capsule combined with anlotinib in the third-line treatment of advanced non-

small cell lung cancer: a retrospective study Manuscript number (if known): JTD-23-1412

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	No. 2018-2-26	The Youth Project of Health and Family Planning Commission
		Time frame: pa	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending	None	
	meetings and/or travel		
		Constitution of the Consti	
			The state of the s
8	Patents planned in		
	Patents planned, issued or pending	None	
	perioring		
9	Participation on a Data		
	Safety Monitoring Board or	None	
	Advisory Board		
10	Leadership or fiduciary role		
	in other board, society,	None	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
		None	
2	Receipt of equipment,	None	
	materials, drugs, medical	one	
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		The state of the s

The author reports that this study was supported by the Youth Project of Health and Family Planning Commission (No. 2018-2-26)							
			1983 10	1300	0.00	35 11	

Please place an "X" next to the following statement to indicate your agreement:

Date: both Septonber, 2013 Your Name: Shugo Wanden

Your Name: The Etoposide soft capsule combined with an Intinib in the third-line treatment of advanced non-

small cell lung cancer: a retrospective study Manuscript number (if known): JTD-23-1412

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	(A) 100 (A) 1	Time frame: Since the initi	
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	No. 2018-2-26	The Youth Project of Health and Family Planning Commission
		Time frame: pa	ist 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	NAME OF THE OWNER OWNER OF THE OWNER OWNE

5	Payment or honoraria for	None	
	lectures, presentations,	None	
	speakers bureaus,		and the same line in the same
	manuscript writing or		
	educational events		
6			
ь	Payment for expert	None	
	testimony		
210			
7	Support for attending	None	COLUMN TO SERVICE AND ADDRESS OF THE PARTY O
	meetings and/or travel		
		CONTRACTOR STATE OF THE PARTY O	
	The Table of the second		
8	Patonts plane at 1		
	Patents planned, issued or	None	
	pending		
2			
9	Participation on a Data	None	THE RESERVE OF THE PARTY OF THE
	Safety Monitoring Board or		
	Advisory Board	A CONTRACTOR OF THE PARTY OF TH	
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
2	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
3	Other financial or non-	None	
	financial interests	INOTIE	CANCELLO DE LA DISTORIA DE LA CONTRACTORIA DEL CONTRACTORIA DE LA CONTRACTORIA DE LA CONTRACTORIA DE LA CONT

The author reports that this stu	idy was supported by the Youth l	Project of Health and Family Pla	anning Commission (No. 2018-2-26)

Please place an "X" next to the following statement to indicate your agreement:

6 th september, 2003 :: Transven Xu Date:

Your Name:

Manuscript Title: Etoposide soft capsule combined with anlotinib in the third-line treatment of advanced non-

small cell lung cancer: a retrospective study Manuscript number (if known): JTD-23-1412

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	THE RESERVE OF THE PROPERTY.	Time frame: Since the initi	al planning of the work
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article	No. 2018-2-26	The Youth Project of Health and Family Planning Commission
	processing charges, etc.)  No time limit for this item.		
8.	THE THE STATE OF STAT	Time frame: pa	st 36 months
	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	None	
,	lectures, presentations, speakers bureaus,	None	
	manuscript writing or educational events		
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation		
3	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical	None	
	writing, gifts or other services		
13	Other financial or non- financial interests	None	

the above conflict of interest in the following box:

Please place an "X" next to the following statement to indicate your agreement: